Apogenix And EMA To Settle On Phase III Plans For PRIME Candidate Asunercept

Apogenix will ask the European Medicines Agency to consider a conditional approval strategy for its novel glioblastoma drug, asunercept, when it meets the regulators in early November.

Tumour
Apogenix and EU regulators are to discuss the next steps for the company's glioblastoma drug • Source: Shutterstock

More from Product Reviews

More from Pink Sheet